A detailed history of Ronald Blue Trust, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 859 shares of BMRN stock, worth $57,235. This represents 0.0% of its overall portfolio holdings.

Number of Shares
859
Previous 142 504.93%
Holding current value
$57,235
Previous $11,000 445.45%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$69.02 - $93.84 $49,487 - $67,283
717 Added 504.93%
859 $60,000
Q2 2024

Jul 18, 2024

BUY
$74.43 - $92.22 $10,569 - $13,095
142 New
142 $11,000
Q4 2023

Jan 18, 2024

BUY
$76.22 - $98.51 $228 - $295
3 Added 7.32%
44 $4,000
Q3 2023

Oct 11, 2023

SELL
$85.07 - $94.48 $85 - $94
-1 Reduced 2.38%
41 $4,000
Q2 2023

Jul 14, 2023

SELL
$86.68 - $100.3 $433 - $501
-5 Reduced 10.64%
42 $4,000
Q1 2023

Apr 17, 2023

BUY
$87.74 - $117.27 $3,597 - $4,808
41 Added 683.33%
47 $5,000
Q4 2022

Jan 17, 2023

BUY
$80.93 - $108.63 $485 - $651
6 New
6 $1,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.